期刊文献+

塞来昔布联合顺铂对人舌鳞癌Tca8113细胞移植瘤的生长抑制作用 被引量:3

Inhibitory effect of celecoxib combined with cisplatin on xenografts of Tca8113 cells in vivo
原文传递
导出
摘要 目的:通过动物实验观察COX-2抑制剂塞莱昔布与顺铂联合应用后对人舌鳞癌Tca8113细胞移植瘤的生长抑制作用。方法:将Tca8113细胞接种于裸鼠皮下,分别给予塞来昔布、顺铂及两者联合应用,35d后处死裸鼠,测移植瘤质量,计算抑瘤率,光镜及电镜观察移植瘤组织学变化,免疫组化染色观察COX-2蛋白的表达,RT-PCR检测COX-2mRNA表达。结果:COX-2抑制剂塞来昔布除抑制Tca8113细胞移植瘤生长及COX-2蛋白的表达外,还显著增强顺铂对移植瘤的生长抑制作用。塞来昔布组、顺铂组及塞来昔布+顺铂组的抑瘤率分别为15.63%、37.50%和82.81%,与对照组相比差异有统计学意义,P<0.01;塞来昔布+顺铂组与塞来昔布及顺铂单独用药组相比,其抑制移植瘤生长差异有统计学意义,P<0.01;塞来昔布对Tca8113细胞COX-2mRNA表达的抑制作用较弱,与对照组相比差异无统计学意义,P=0.073。结论:塞来昔布除了可以抑制裸鼠移植瘤生长外,还可以增强顺铂对Tca8113细胞裸鼠移植瘤生长抑制作用,其作用机制可能与抑制COX-2蛋白的表达有关,为进一步探索抑制COX-2酶的活性与防治头颈肿瘤的作用机制方面,提供了有益的参考。 OBJECTIVE:To investigate the inhibitory role of celecoxib combined with cisplatin(DDP) on human tongue squamous cell carcinoma cell line Tca8113 in vivo.METHODS:Nude mice bearing xenografts were treated with as follows:celecoxib,DDP,and celecoxib plus DDP and control.At 35 d after administration,the nude mice were sacrificed and tumor masses were dissected and weighed for calculating tumor inhibition rates.The histological and electron microscopic analyses were used to observe the nude mouse tumor tissues.The immunohistochemistry staining was employed for COX-2 protein expression and fluorescent quantitive real-time RT-PCR was used to detect COX-2 mRNA expression.RESULTS:COX-2 proteins were strongly expressed in the control group while their expressions were significantly decreased in the groups of celecoxib and celecoxib plus DDP.COX-2 inhibitor celecoxib could enhance the inhibition of DDP on the growth of Tca8113 xenograft.The inhibition rates in the celecoxib group,DDP group and celecoxib plus DDP group were 15.63%,37.50% and 82.81%,respectively,which were statistically significant compared with the control group (P〈0.01).Compared with celecoxib and DDP groups,the inhibitory effect of celecoxib plus DDP was statistically significant (P〈0.01).The results of RT-PCR showed that celecoxib was less active in inhibiting the expression of COX-2 mRNA (P=0.073).CONCLUSIONS:COX-2 inhibitor celecoxib is capable of enhancing the killing effect of DDP on Tca8113 cells.When co-administered with DDP,the inhibitory effect of DDP on the growth of xenografts in nude mice is significantly enhanced.
出处 《中华肿瘤防治杂志》 CAS 2010年第8期579-583,共5页 Chinese Journal of Cancer Prevention and Treatment
基金 广东省自然科学基金(06024396)
关键词 环氧化酶2 塞来昔布 鳞状细胞 舌肿瘤 移植瘤 顺铂 cyclooxygenase 2 celecoxib carcinoma squamous cell tongue neoplasms cisplatin
  • 相关文献

参考文献12

  • 1李伟忠,丁彦青,李祖国,张进华.COX-2和VEGF-C在舌癌组织中的表达及与颈淋巴结转移的关系[J].南方医科大学学报,2008,28(2):180-183. 被引量:9
  • 2李伟忠,王晓燕,李祖国,张进华,丁彦青.塞来昔布增强博来霉素对人舌鳞状细胞癌Tca8113杀伤作用的研究[J].中华口腔医学杂志,2009,44(3):140-143. 被引量:7
  • 3Doherty G A, Murray F E. Cyclooxygenase as a target for chemoprevention in colorectal cancer: lost cause or a concept coming of age? [J]. Expert Opin Ther Targets, 2009,13(2):209-218.
  • 4宋娜,金波,刘云鹏,于萍.非小细胞肺癌组织COX-2和p53表达及其临床意义的研究[J].中华肿瘤防治杂志,2008,15(16):1247-1250. 被引量:4
  • 5Yu L, Wu W K, Li Z J, et al. Enhancement of doxorubicin cytotoxicity on human esophageal squamt)us cell carcinoma cells by indomethacin and 4-[5-( 4-chlorophenyl)-3-( trifluoromethyl )- 1H-pyrazol-l-yl] benzenesulfonamide (SC236) via inhibiting P- glycoprotein activity [J]. Mol Pbarmacol, 2009, 75 (6) :1364-1373.
  • 6Mizutani Y, Nakanishi H, Li Y N, et al. Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and ap optosis in vitro and in vivo by the selective cyclooxygenase 2 inhibitorJTE-522[J]. J Urol, 2004, 172(4Pt 1):1474-1479.
  • 7Lin J, Hsiao P W, Chiu T H, et al. Combination of cyelooxyge nase 2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells[J]. Biochemical Pharmacology, 2005, 70(5): 658- 667.
  • 8Naruse T, Nishida Y, Ishiguro N. Synergistic effects of meloxicam and conventional cytotoxic drugs in human MG-63 osteosarcoma cells[J]. Biomed Pharmacother, 2007, 61(6) :338-346.
  • 9Hashitani S, Urade M, Nisbimura N, et al. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by Celecoxib, a selective cyclooxygenase 2 inhibitor, in human head and neck carcinoma cell line[J], Int J Oncol, 2003, 23 (3):665-672.
  • 10de Groot D J, de Vries E G, Groen H J, et al. Non-steroidal an tiinflammatory drugs to potentiate chemotherapy effects: from lab to clinic[J]. Crit Rev Oncol Hematol, 2007, 61(1) :52-69.

二级参考文献46

  • 1廖美琳.肺癌多学科治疗的新进展[J].肿瘤防治杂志,2004,11(7):764-767. 被引量:13
  • 2石晶,陈谦明.环氧化酶2抑制剂:预防与治疗口腔黏膜癌变的新途径[J].中华口腔医学杂志,2005,40(3):262-264. 被引量:4
  • 3金正均.合并用药中的相加[J].中国药理学报,1980,1:70-73.
  • 4Campling B G, el Deiry W S. Clinical implications of p53 mutations in lung cancer[J]. Methods Mol Med, 2003, 75(1) : 53-77.
  • 5McLaren R, Kuzu I, Dunnill M, et al. The relationship of p53 immunostaining to survival in carcinoma of the lung[J]. Br J Cancer, 1992, 66(4) :735-738.
  • 6Benoit V, de-Moraes E, Dar N A, et al. Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nucle ar factor-kappaB[J]. Oncogene, 2006, 25(42): 5708-5718.
  • 7Chow L W, Loo W T, Wai C C, et al. Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients[J]. Biomed Pharmacotber, 2005, 59 (Suppl 2): 298-301.
  • 8Kim K H, Park E J, Seo Y J, et al. Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors[J]. J Dermatol, 2006, 33(5): 319-325.
  • 9Parkin D M, Bray F, Ferlay J, et al. Global Cancer Statistics. 2002[J]. CA Cancer J Clin, 2005, 55(2): 74-108.
  • 10Yang L, Parkin D M, Ferlay J, et al. Estimates of cancer incidence in China for 2000 and projection for 2005[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(1):243-250.

共引文献16

同被引文献32

  • 1Kim SH, Kim SH, Song YC, et al. Celecoxib potentiates the anticaneer effect of cisplatin on vulvar cancer ceils independently of eyclooxygenase[J].Ann N Y Acad Sci, 2009,1171 : 635-641.
  • 2Li WZ, Huo Qj, Wang XY, et al. Inhibitive effect of eelecoxib on the adhesion and invasion of human tongue squamous carcino- ma cells to extracellular matrix via down regulation of MMP-2 expression[J]. Prostaglandins BOther Lipid Mediators, 2010, 93(3-4) : 113-119.
  • 3Baguley BC. Multiple drug resistance mechanisms in cancer[J]. Mol Biotechnol, 2010, 46(3)..308-316. Stavrovskaya AA, Stromskaya TP. Transport proteins of the ABC family and multidrug resistance of tumor cells[J]. Bio- chemistry(Mosc), 2008,73(5) ; 592-604.
  • 4Stavrovskaya AA, Stromskaya TP. Transport proteins of the ABC family and multidrug resistance of tumor cells[J]. Bio- chemistry(Mosc), 2008,73(5) : 592-604.
  • 5Lee JY, Tanabe S, ShimohiraH, et al. Expression of cyclooxy- genase-2, P-glycoprotein and multi-drug resistance-associated protein in canine transitional cell carcinoma[J]. Res Vet Sci, 2007,83(2): 210-216.
  • 6Fantappib O, Solazzo M, Lasagna N, et al. P-glycoprotein me- diates celecoxib-induced apoptosis in multiple drug-resistant cell lines[J]. Cancer Res, 2007,67(10): 4915-4923.
  • 7Li WZ, Wang XY, Li ZG, et al. Celecoxib enhances the inhibi- tory effect of Tea8113 cells in human tongue squamous cell carci- noma in vivo and vitro[J]. J Oral Pathol Med, 2010,39(7): 579-584.
  • 8Zatelli MC, Luchin A, Tagliati F, et al. Cyclooxygenase-2 inhib- itors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression [J]. Endocr Relat Cancer, 2007,14(4) : 1029-1038.
  • 9Arunasree KM, Roy KR, Anilkumar K, et al. Imatinib-resist- ant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1[J]. Leuk Res, 2008, 32 (6) ,855-864.
  • 10Zrieki A, Farinotti R, Buyse M. Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal caeo-2 cell line[J]. Phar- maceutical Research, 2008,25(9) : 1991-2001.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部